Philippines vs United Arab Emirates: Share of S. aureus infections resistant to methicillin
Philippines
44.4%
in 2022
United Arab Emirates
39.9%
in 2022
Philippines rank
13th
United Arab Emirates rank
15th
Share of S. aureus infections resistant to methicillin over time
- Philippines
- United Arab Emirates
How they compare
Philippines currently reports 44.4% against 39.9% in United Arab Emirates, a difference of 4.5%.
That makes Philippines's figure about 1.1 times United Arab Emirates's.
Across all 6 years both countries report, Philippines has been ahead every year.
Philippines ranks 13th and United Arab Emirates ranks 15th of 45 countries.
Philippines has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Philippines | United Arab Emirates | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 54.8% | 31.3% | 23.4% | Philippines |
| 2020s | 44.9% | 39.4% | 5.6% | Philippines |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of s. aureus infections resistant to methicillin, Philippines or United Arab Emirates?
- Philippines, at 44.4% against 39.9% in United Arab Emirates as of 2022.
- What is the difference in share of s. aureus infections resistant to methicillin between Philippines and United Arab Emirates?
- 4.5%, with Philippines ahead.
- How many years of comparable data are there for Philippines and United Arab Emirates?
- 6 years are reported by both, from 2017 to 2022.
- How do Philippines and United Arab Emirates rank globally for share of s. aureus infections resistant to methicillin?
- Philippines ranks 13th and United Arab Emirates ranks 15th of 45 countries.
- Where does this data come from?
- World Health Organization – processed by Our World in Data, published as Share of S. aureus infections resistant to methicillin. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested (%).